Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-Prion Activity of Brilliant Blue G

31 May 2012

Abstract excerpt

BACKGROUND: Prion diseases are fatal neurodegenerative disorders with no effective therapy currently available. Accumulating evidence has implicated over-activation of P2X7 ionotropic purinergic receptor (P2X7R) in the progression of neuronal loss in several neurodegenerative diseases. This has led to the speculation that simultaneous blockade of this receptor and prion replication can be an effective therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to Amyotrophic Lateral Sclerosis Research
Share to Prion Diseases and Protein Misfolding

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22693582
DOI: 10.1371/journal.pone.0037896

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-Prion Activity of Brilliant Blue GPMID 22693582Read ↗

Phenotypic screening for small molecules that lower PrP in cultured cellsSemantic proximity Read ↗

Divalent siRNA for prion diseaseSemantic proximity Read ↗

A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein.Semantic proximity Read ↗

Sigma receptor ligands are potent anti-prion compounds that act independently of sigma receptor bindingSemantic proximity Read ↗

Approaches for discovering anti-prion compounds: lessons learned and challenges ahead.Semantic proximity Read ↗

Characterizing antiprion compounds based on their binding properties to prion proteins: Implications as medical chaperonesSemantic proximity Read ↗

Therapeutic strategies for identifying small molecules against prion diseasesSemantic proximity Read ↗

Hippocampal purinergic P2X7 receptor level is increased in Alzheimer’s disease patients, and associated with amyloid and tau pathologiesSemantic proximity Read ↗

The P2X7 receptor: a new therapeutic target in Alzheimer’s diseaseSemantic proximity Read ↗

Discovery of 2-Aminothiazoles as Potent Antiprion CompoundsSemantic proximity Read ↗

Prion protein lowering is a disease-modifying therapy across prion disease stages, strains, and endpointsSemantic proximity Read ↗

Characterization of the prion protein binding properties of antisense oligonucleotidesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.